WO2002043666A2 - Composition et methode - Google Patents

Composition et methode Download PDF

Info

Publication number
WO2002043666A2
WO2002043666A2 PCT/US2001/048665 US0148665W WO0243666A2 WO 2002043666 A2 WO2002043666 A2 WO 2002043666A2 US 0148665 W US0148665 W US 0148665W WO 0243666 A2 WO0243666 A2 WO 0243666A2
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
cognitive function
day
deterioration
carnitine
Prior art date
Application number
PCT/US2001/048665
Other languages
English (en)
Other versions
WO2002043666A3 (fr
Inventor
Steven Curtis Zicker
Karen J. Wedekind
Original Assignee
Colgate-Palmolive Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/922,633 external-priority patent/US20020052402A1/en
Application filed by Colgate-Palmolive Company filed Critical Colgate-Palmolive Company
Priority to CA002427470A priority Critical patent/CA2427470A1/fr
Priority to JP2002545645A priority patent/JP2004514686A/ja
Priority to AU2002232616A priority patent/AU2002232616A1/en
Priority to EP01992146A priority patent/EP1339404A2/fr
Publication of WO2002043666A2 publication Critical patent/WO2002043666A2/fr
Publication of WO2002043666A3 publication Critical patent/WO2002043666A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • This deterioration of cognitive function in older humans can now be prevented, inhibited or treated with specific components. These components can be administered in the diet or taken separately orally.
  • composition comprising an antioxidant or mixture thereof quantities sufficient to a. prevent or b. inhibit, or r c. reverse deterioration of cognitive function
  • a further aspect is a method of preventing, inhibiting or reversing deterioration of cognitive function through the administration of this composition.
  • an antioxidant is a material that quenches a free radical.
  • examples of such materials are beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1- carnitine and the like.
  • Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like Vitamin E acetate, succinate, palmitate, and the like.
  • the alpha form is preferable but beta, gamma and delta forms can be included.
  • the d form is preferable but racemic mixtures are acceptable.
  • the forms and derivatives will function in a Vitamin E like activity after ingestion.
  • Vitamin C can be administered as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the human. They can be in any form such as liquid, semisolid, solid and heat stable form.
  • Alpha-lipoic acid can be administered as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621, 117, racemic mixtures, salts, esters or amides thereof.
  • L-carnitine and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinate s, as well as acetylated carnitine, and the like can be used.
  • the quantities administered to the human are calculated as the active material, per se, that is measured as specific material.
  • the minimum amounts employed should not bring about toxicity.
  • Vitamin E minimum is about 50 or 100 or 150 mg/day. Generally, no more than about 2,000 or desirably about 1,000 or about 750 mg/day can be employed.
  • Vitamin C minimum quantities are generally about 150, about 200 or about 250 mg/day. Maximums generally do not exceed about 1,000 mg/day but can be lower, for example, about 900 or about 750 mg/day.
  • Alpha lipoic acid can be administered up to about 10 or 20 mg/kg body weight/ day. Minimums are about .5 or 1 mg/kg body weight/ day.
  • L-carnitine is administered in the same manner as alpha lipoic acid. Alpha lipoic acid and l-carnitine can be administered at much higher levels but there is no substantially different efficacy observed.
  • Beta-carotene at least about 0.02 mg/kg body weight/ day 1-15 ppm can be employed.
  • Lutein at least about 5 ppm mg/kg body weight/ day can be employed.
  • Tocotrienols at least about 0.5 mg/kg body weight/ day can be employed.
  • Coenzyme Q10 at least about 0.5 mg/kg body weight/ day can be employed.
  • S-adenosylmethionine at least about 1.0 mg/kg body weight/ day can be employed.
  • Taurine at least about 10 mg/kg body weight/ day can be employed.
  • Soy isoflavones at least about 0.5 mg/kg body weight/ day can be used.
  • N-acetylcysteine at least about 1.0 mg/kg/ body weight/ day can be used.
  • Glutathione at least about 1.0 g/kg body weight/ day can be used.
  • Ginkgo Biloba at least 1.0 mg/kg body weight/ day can be used.
  • the quantities can be administered in a typical "one a day" dosage similar to a vitamin. It can be administered in tablet, capsule, caplet for example, or in a liquid carrier form all for ingestion by the human. Additionally, the daily dosage can be broken down into two, three, or four dosage unit forms for convenience or other reasons. Additionally, it can be administered in a food such as snack bars, cereals, and the like.
  • Example 1
  • a supplement or food providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of l-carnitine is eaten by an adult human on a daily basis for 5 years starting at age 45.
  • age of 50 no signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or health care provider, are observed.
  • MME Folstein's Mini-mental State Exam
  • WMS Wechsler Memory Scale
  • Katz' scale of activities of daily living Lawton's scale of instrumental activities of daily living
  • Pfeiffer's mental status questionnaire or other pertinent tests as
  • MME Folstein's Mini-mental State Exam
  • WMS Wechsler Memory Scale
  • Katz' scale of activities of daily living Lawton's scale of instrumental activities of daily living

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition renfermant un antioxydant ou un mélange d'antioxydants en quantités suffisantes pour prévenir, inhiber, ou inverser la détérioration de la fonction cognitive.
PCT/US2001/048665 2000-10-31 2001-10-30 Composition et methode WO2002043666A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002427470A CA2427470A1 (fr) 2000-10-31 2001-10-30 Composition et methode
JP2002545645A JP2004514686A (ja) 2000-10-31 2001-10-30 組成物と方法
AU2002232616A AU2002232616A1 (en) 2000-10-31 2001-10-30 Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin C or vitamin E for preventing or inhibiting loss of cognitive function
EP01992146A EP1339404A2 (fr) 2000-10-31 2001-10-30 Composition et methode

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24451100P 2000-10-31 2000-10-31
US60/244,511 2000-10-31
US25344600P 2000-11-28 2000-11-28
US25344700P 2000-11-28 2000-11-28
US60/253,447 2000-11-28
US60/253,446 2000-11-28
US09/922,633 2001-08-06
US09/922,633 US20020052402A1 (en) 2000-10-31 2001-08-06 Composition and method

Publications (2)

Publication Number Publication Date
WO2002043666A2 true WO2002043666A2 (fr) 2002-06-06
WO2002043666A3 WO2002043666A3 (fr) 2003-01-30

Family

ID=27500158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048665 WO2002043666A2 (fr) 2000-10-31 2001-10-30 Composition et methode

Country Status (6)

Country Link
EP (1) EP1339404A2 (fr)
JP (1) JP2004514686A (fr)
CN (1) CN1477958A (fr)
AU (1) AU2002232616A1 (fr)
CA (1) CA2427470A1 (fr)
WO (1) WO2002043666A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185188A (ja) * 2003-12-25 2005-07-14 Nichirei Corp アセロラ処理物およびｌ−カルニチン含有組成物
AU2005211165B2 (en) * 2004-01-28 2011-02-24 Nestec S.A. Nutritional composition for improving skin condition and preventing skin diseases
EP2508179A1 (fr) 2011-04-05 2012-10-10 Lonza Ltd. Utilisation de carnitine L, sels et dérivés associés pour réduire ou empêcher la fatigue et améliorer la fonction cognitive
WO2012136699A1 (fr) 2011-04-05 2012-10-11 Lonza Ltd. Utilisation de l-carnitine, sels et dérivés de celle-ci pour réduire ou prévenir la fatigue et améliorer la fonction cognitive
US20120288608A1 (en) * 2009-07-14 2012-11-15 Hill's Pet Nutrition, Inc. Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof
WO2021118359A1 (fr) 2019-12-11 2021-06-17 Sulfateq B.V. Composés pour le traitement de la maladie d'alzheimer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005309502B2 (en) * 2004-11-24 2011-11-17 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
BRPI0518580A2 (pt) * 2004-11-24 2008-11-25 Hills Pet Nutrition Inc mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
WO2007022344A2 (fr) * 2005-08-17 2007-02-22 Hill's Pet Nutrition, Inc. Procedes et compositions permettant de prevenir et de traiter les maladies renales
CN1895671B (zh) * 2005-12-08 2012-11-28 淮北辉克药业有限公司 治疗病毒型肝病的复方制剂
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
EP2123263A1 (fr) * 2007-02-14 2009-11-25 Tohoku University Composition et procédé pour supprimer la péroxydation des lipides dans les érythrocytes

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343592A1 (de) * 1993-12-21 1995-06-22 Asta Medica Ag Verwendung von R-(+)alpha-Liponsäure, R-(-)-Dihydroliponsäure und deren Metabolite in Form der freien Säure oder als Salze oder Ester oder Amide zur Herstellung von Arzneimitteln zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystem
US5853747A (en) * 1994-06-27 1998-12-29 Institut De Recherche Biologique Therapeutic and dietetic uses of a brain phospholipid-based complex
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
DE19920316A1 (de) * 1999-05-03 1999-12-09 Heinz Kiefer Arzneimittel als Antioxidans mit einer Vitamin-Spurenelement-Kombination zur Förderung der Funktionstüchtigkeit der Zellen
WO2000011968A1 (fr) * 1998-09-01 2000-03-09 Sigma-Tau Healthscience S.P.A. Composition antioxydante renfermant de l'acetyl-l-carnitine et de l'acide alpha-lipoique
WO2000054754A2 (fr) * 1999-03-16 2000-09-21 Merck Patent Gmbh Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee
WO2000057876A1 (fr) * 1999-03-26 2000-10-05 Lipogenics, Inc. Preparations antioxydantes et procedes d'utilisation de telles preparations
WO2000076492A1 (fr) * 1999-06-15 2000-12-21 Nutri-Logics, Inc. Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
WO2001032168A1 (fr) * 1999-11-03 2001-05-10 Juvenon, Inc. Traitement de la perte de memoire benigne
WO2001058271A1 (fr) * 2000-01-25 2001-08-16 Juvenon, Inc. Supplements nutritionnels pour animaux de compagnie ages
WO2001070206A2 (fr) * 2000-03-06 2001-09-27 Javor Andras Combinaison de medicaments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199690A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 脳代謝促進・脳機能改善剤

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343592A1 (de) * 1993-12-21 1995-06-22 Asta Medica Ag Verwendung von R-(+)alpha-Liponsäure, R-(-)-Dihydroliponsäure und deren Metabolite in Form der freien Säure oder als Salze oder Ester oder Amide zur Herstellung von Arzneimitteln zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystem
US5853747A (en) * 1994-06-27 1998-12-29 Institut De Recherche Biologique Therapeutic and dietetic uses of a brain phospholipid-based complex
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
WO2000011968A1 (fr) * 1998-09-01 2000-03-09 Sigma-Tau Healthscience S.P.A. Composition antioxydante renfermant de l'acetyl-l-carnitine et de l'acide alpha-lipoique
WO2000054754A2 (fr) * 1999-03-16 2000-09-21 Merck Patent Gmbh Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee
WO2000057876A1 (fr) * 1999-03-26 2000-10-05 Lipogenics, Inc. Preparations antioxydantes et procedes d'utilisation de telles preparations
DE19920316A1 (de) * 1999-05-03 1999-12-09 Heinz Kiefer Arzneimittel als Antioxidans mit einer Vitamin-Spurenelement-Kombination zur Förderung der Funktionstüchtigkeit der Zellen
WO2000076492A1 (fr) * 1999-06-15 2000-12-21 Nutri-Logics, Inc. Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
WO2001032168A1 (fr) * 1999-11-03 2001-05-10 Juvenon, Inc. Traitement de la perte de memoire benigne
WO2001058271A1 (fr) * 2000-01-25 2001-08-16 Juvenon, Inc. Supplements nutritionnels pour animaux de compagnie ages
WO2001070206A2 (fr) * 2000-03-06 2001-09-27 Javor Andras Combinaison de medicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199433 Derwent Publications Ltd., London, GB; Class B05, AN 1994-269367 XP002210667 & JP 06 199690 A (KATO K), 19 July 1994 (1994-07-19) *
POULIN J E ET AL: "Vitamin E prevents oxidative modification of brain and lymphocyte band 3 proteins during aging." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 28 MAY 1996, vol. 93, no. 11, 28 May 1996 (1996-05-28), pages 5600-5603, XP002210596 ISSN: 0027-8424 *
See also references of EP1339404A2 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185188A (ja) * 2003-12-25 2005-07-14 Nichirei Corp アセロラ処理物およびｌ−カルニチン含有組成物
AU2005211165B2 (en) * 2004-01-28 2011-02-24 Nestec S.A. Nutritional composition for improving skin condition and preventing skin diseases
AU2005211165A8 (en) * 2004-01-28 2011-07-14 Nestec S.A. Nutritional composition for improving skin condition and preventing skin diseases
AU2005211165B8 (en) * 2004-01-28 2011-07-14 Nestec S.A. Nutritional composition for improving skin condition and preventing skin diseases
US20120288608A1 (en) * 2009-07-14 2012-11-15 Hill's Pet Nutrition, Inc. Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof
EP2508179A1 (fr) 2011-04-05 2012-10-10 Lonza Ltd. Utilisation de carnitine L, sels et dérivés associés pour réduire ou empêcher la fatigue et améliorer la fonction cognitive
WO2012136699A1 (fr) 2011-04-05 2012-10-11 Lonza Ltd. Utilisation de l-carnitine, sels et dérivés de celle-ci pour réduire ou prévenir la fatigue et améliorer la fonction cognitive
US10130602B2 (en) 2011-04-05 2018-11-20 Lonza Ltd. Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
WO2021118359A1 (fr) 2019-12-11 2021-06-17 Sulfateq B.V. Composés pour le traitement de la maladie d'alzheimer
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Also Published As

Publication number Publication date
WO2002043666A3 (fr) 2003-01-30
CA2427470A1 (fr) 2002-06-06
EP1339404A2 (fr) 2003-09-03
AU2002232616A1 (en) 2002-06-11
CN1477958A (zh) 2004-02-25
JP2004514686A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
US7012092B2 (en) Formulation and delivery method to enhance antioxidant potency of Vitamin E
US9278109B2 (en) Compositions and methods for the prevention of cardiovascular disease
US6121249A (en) Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
WO2002043666A2 (fr) Composition et methode
US20020076470A1 (en) Composition and method
US6323188B1 (en) Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
US20060116334A1 (en) Folate based composition for treatment of the cardiovascular system
EP2869717B1 (fr) Prévention d'une réaction à l'alcool avec des compléments diététiques
US10052316B2 (en) Methods and compositions for treatment of mitochondrial toxicity
EP1331855B1 (fr) Composition pour animaux de compagnie agés
WO2001021208A1 (fr) Supplement nutritionnel fournissant une energie et une endurance accrues
CA2284290A1 (fr) Complement nutritionnel destine a favoriser une bonne sante cardio-vasculaire
ES2546055T3 (es) Complementos nutricionales para individuos de 50 años o más para mejorar la vitalidad, la inmunidad, la salud ocular y ósea
KR20070111478A (ko) 영양 보충을 위한 조성물과 방법
US20080181972A1 (en) Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
US20130084272A1 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
JP2008214338A (ja) 高次脳機能低下改善剤および遅延記憶低下改善剤
US20020076469A1 (en) Composition and method
US20020052402A1 (en) Composition and method
BR112020016923A2 (pt) Método para reverter ou atenuar lesão, ou fraqueza ou perda óssea, ou para evitar fraturas em um indivíduo, e, composição
US7628984B2 (en) Micronutrient formulations for pulmonary and heart health
US7399755B2 (en) Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same
ZA200303749B (en) Compositions containing an antioxidant such as alpha lipoic acid, carnitine, Vitamin C or Vitamin E for preventing or inhibiting loss of cognitive function.
US6358997B1 (en) Tocopherol and tocotrienol compositions
AU2232300A (en) Vitamin formulation for cardiovascular health

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 018181880

Country of ref document: CN

Ref document number: 2427470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002545645

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002232616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/03749

Country of ref document: ZA

Ref document number: 200303749

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001992146

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001992146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001992146

Country of ref document: EP